Elizabeth A. Punnoose

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Klaus W. Wagner, Elizabeth A. Punnoose, Thomas Januario et al. · Nature Medicine · 2007 · 603 citations

Life Sciences, Cell Biology, Oncology +16

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto et al. · Blood · 2017 · 527 citations · Full text

Medicine, Hematology, Immunology +11

<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd et al. · Clinical Cancer Research · 2009 · 473 citations

Medicine, Oncology, Pharmacology +17

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu et al. · Clinical Cancer Research · 2012 · 417 citations

Medicine, Nuclear Medicine, Oncology +17